PASS

Pharma · IBM Heron r2 · ibm_kingston · job da0bkvv2sl0c73bmtf2g

Photodynamic therapy
agent selection

Therapy-only panel. Locked expectation: talaporfin outranks padeliporfin under co-resident efficacy, toxicity, and selectivity.

What the case is

Choose among five marketed PDT drugs used as therapy. Three goals at once: kill the target, spare tissue, stay selective. Efficacy, toxicity, and selectivity co-reside in one job.

Goal

Verify F2-E1: talaporfin (Laserphyrin) > padeliporfin (Tookad) on coupled raw priority, against equal-weight classical.

How it was prepared

How it was computed

IBM Heron r2 · ibm_kingston · 4096 shots · job da0bkvv2sl0c73bmtf2g. Transjunctions computed on the QPU. Primary readout: raw counts. Resilience is a labelled diagnostic channel on the same job.

How it was evaluated

PASS when the locked pair order holds on raw QPC priority. Full ranking is reported. The industry finding is the pair.

PASS
F2-E1
0.546
talaporfin
0.493
padeliporfin
+0.053
Margin
verteporfin
0.609
talaporfin
0.546
padeliporfin
0.493
temoporfin
0.435
porfimer
0.414
Full PDT report Atlas